Pseudoprogression and Pseudoresponse in the Management of High-Grade Glioma : Optimal Decision Timing According to the Response Assessment of the Neuro-Oncology Working Group-Reference-Cited by-同舟云学术

Pseudoprogression and Pseudoresponse in the Management of High-Grade Glioma : Optimal Decision Timing According to the Response Assessment of the Neuro-Oncology Working Group

Published:2014 Issue:1 Volume:55 Page:5
ISSN:2005-3711
Container-title:Journal of Korean Neurosurgical Society
language:en
Short-container-title:J Korean Neurosurg Soc

Author:

Chang Ji Hyun¹,Kim Chae-Yong²,Choi Byung Se³,Kim Yu Jung⁴,Kim Jae Sung¹,Kim In Ah¹

Affiliation:

1. Department of Radiation Oncology, Seoul National University Bundang Hospital, Seongnam, Korea.

2. Department of Neurosurgery, Seoul National University Bundang Hospital, Seongnam, Korea.

3. Department of Radiology, Seoul National University Bundang Hospital, Seongnam, Korea.

4. Department of Internal Medicine, Seoul National University Bundang Hospital, Seongnam, Korea.

Publisher

Korean Neurosurgical Society

Subject

Clinical Neurology,General Neuroscience,Surgery

Link

http://www.jkns.or.kr/upload/pdf/jkns-55-5.pdf

Reference29 articles.

1. MGMTPromoter Methylation Status Can Predict the Incidence and Outcome of Pseudoprogression After Concomitant Radiochemotherapy in Newly Diagnosed Glioblastoma Patients

2. Imaging modalities in high-grade gliomas: Pseudoprogression, recurrence, or necrosis?

3. Bevacizumab for the Treatment of Recurrent Glioblastoma

4. Pseudoprogression after radiotherapy with concurrent temozolomide for high-grade glioma: clinical observations and working recommendations

5. Canadian Recommendations for the Treatment of Recurrent or Progressive Glioblastoma Multiforme

Cited by 17 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Identification of prognostic risk score of disulfidptosis-related genes and molecular subtypes in glioma;Biochemistry and Biophysics Reports;2024-03

2. Surgical management of Glioma Grade 4: technical update from the neuro-oncology section of the Italian Society of Neurosurgery (SINch®): a systematic review;Journal of Neuro-Oncology;2023-03-24

3. AI + precision medicine;The Thinking Healthcare System;2023

4. A Clinical PET Imaging Tracer ([18F]DASA-23) to Monitor Pyruvate Kinase M2–Induced Glycolytic Reprogramming in Glioblastoma;Clinical Cancer Research;2021-09-02

5. Assessment of the effect of therapy in a rat model of glioblastoma using [18F]FDG and [18F]FCho PET compared to contrast-enhanced MRI;PLOS ONE;2021-03-05